Investors in Oncology

Radforsk Invest's role goes far beyond traditional financing when we work to develop our portfolio companies. We are both investors, entrepreneurs and company developers. Ground-breaking new cancer treatment takes time to develop, and with our evergreen model we are long-term.

Malin invests in and supports highly innovative life sciences companies developing cutting-edge science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Headquartered in Ireland and listed on the Euronext Growth Market of Euronext Dublin, Malin aims to generate substantial returns for shareholders through long-term capital and strategic support to its investee companies. Focused on therapeutic areas like oncology, immunology, and genetic diseases, Malin prioritizes business integrity, collaboration with talented individuals, and the development of groundbreaking therapies where current treatments are inadequate.

Seroba is a leading European life sciences venture capital firm, dedicated to creating value by supporting innovative biotech and medtech companies. With a focus on breakthrough technologies, Seroba has backed significant advancements such as Shorla Oncology's FDA-approved TEPYLUTE, a ready-to-dilute formulation for treating breast and ovarian cancer. Based in Dublin, Seroba leverages deep industry expertise to help entrepreneurs build world-class businesses, fostering extraordinary scientific innovations.